AzTrials
AzTrials

Plasmodium Falciparum InfectionNCT05025761

Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Myanmar

A study testing Personal protection package in people with Plasmodium Falciparum Infection, run by Macfarlane Burnet Institute for Medical Research and Public Health Ltd.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This stepped-wedge cluster-randomized controlled trial with nested mixed methods study will assess the effectiveness, acceptability, feasibility and cost effectiveness of a personal protection package to reduce malaria transmission among mobile and migrant populations (MMPs) and the general population in their… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Plasmodium Falciparum Infection
What is being tested?
Personal protection package
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,200 participants
Where
No sites listed yet
Study dates
1 Jan 2022to Jun 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Capacity of Burnet Institute Myanmar to conduct field implementation
  • Presence of ICMV networks managed by NMCP and HPA
  • High malaria burden
  • High MMP activities
  • Available budget
  • Participants selected purposively from the same cohort of MMPs who have received the personal protection package during the study period
Show all 14Show fewer
  • Inclusion criteria for semi-structured interviews with local health stakeholders:
  • Aged over 18 years
  • From different levels of NMCP, EHOs and HPA
  • Basic health staff such as Public Health Supervisors, Midwives, Health Assistants, Township Health Officers and focal person from Township VBDC/NMCP offices
  • Health staff from ethnic health organizations such as medics, doctors and nurses
  • Health staff from HPA such as field supervisor, field office manager, technical officer
  • Inclusion criteria for semi-structured interviews with ICMVs:
  • ICMV participants will be selected purposively from the ICMVs actively working in the selected villages.

Who cannot join

  • The township does not have an NMCP or HPA-provided ICMV network
  • The township is not under the administration of NMCP or HPA
  • The township has an ongoing armed conflict at the time of sampling
  • The location of the township is not geographically or politically feasible for the NMCP or HPA staff to conduct regular supervision visits
  • The village has no malaria cases or API less than 1 in any of the past three years (2018 - 2020)
  • The village has no MMPs
Show all 13Show fewer
  • The village has no ICMVs actively working in the village
  • The village has a government health facility for malaria services
  • The village has an ICMV program operated by any organizations other than NMCP or HPA
  • Inclusion Criteria for MMP participants (personal protection package intervention):
  • Currently living in the selected villages/ worksites
  • Being any of the following types of workers: Traditional slash-and-burn and paddy field farming communities visiting their forest farms (commonly ethnic minority groups); Seasonal agricultural laborers; Forest workers in the informal sector (hunters, small-scale gem/gold miners, people gathering forest products (precious timber, construction timber, rattan/bamboo); Transient or mobile camp residents associated with commercial projects (road/pipeline construction, large-scale logging, deep seaport projects, etc.); Formal and informal cross-border migrant workers
  • Aged 18 years and over

Trial locations and contacts

No sites are listed yet.

Freya JI Fowkes, DPhil contact

+61385062310

freya.fowkes@burnet.edu.au

Win Han Oo, PhD contact

+951375785

winhan.oo@burnet.edu.au

About this study

Official title: A Personal Protection Package for Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Myanmar: A Stepped-wedge Trial With Nested Mixed-methods Study

This stepped-wedge cluster-randomized controlled trial with nested mixed methods study will assess the effectiveness, acceptability, feasibility and cost effectiveness of a personal protection package to reduce malaria transmission among mobile and migrant populations (MMPs) and the general population in their residing villages in Myanmar.

Read the detailed description

Over the last decade, the burden of malaria has fallen dramatically in the Greater Mekong Subregion, with deaths falling by 95% and cases by 76% between 2012 and 2019.The declining malaria burden in GMS has largely been attributed to the deployment of interventions of malaria prevention tools such as long-lasting Insecticidal Nets (LLIN), and widespread availability of rapid diagnostic tests and artemisinin combination therapies. However, residual transmission exists among high risk populations, particularly mobile and migrant populations who enter forests for work. New interventions targetting these high risk groups are needed if countries of the Greater Mekong Subregion are to achieve malaria elimination by 2030. The study will be conducted in malaria endemic areas of Myanmar which have large forest going MMP populations. The aim of the study is to assess the effectiveness, acceptability, feasibility and cost-effectiveness of a personal protection package to reduce malaria transmission among mobile and migrant populations (MMPs) and the general population in their residing villages in Myanmar. The personal protection package includes WHO prequalified long-lasting insecticidal net (LLIN), insect repellent (N, N-Diethyl-meta-toluamide (DEET), insecticide-treated clothes (ITC), and a MMP-tailored behavioural change communication (BCC) package. The study design is a stepped-wedge cluster-randomized controlled trial with nested mixed methods study. The stepped-wedge cluster randomized trial will estimate the effectiveness of a personal protection package provided to forest-going MMPs (the intervention) delivered by village malaria volunteers at the site (village/worksite) level on reducing Plasmodium spp. infections (primary outcome). Whilst the personal protection package will be provided to mobile and migrant populations in each village in a step-wise manner, primary and secondary outcomes relating to malaria testing will be collected in all consenting individuals in the village who present for malaria rapid diagnostic tests, whether they are mobile and migrant people or not. The study will also include investigation of antibody responses to Plasmodium spp. and mosquito vectors and molecular markers of antimalarial drug resistance.

The study will be implemented between July 2021 (M1) to June 2022 (M12). The personal protection package for MMPs will be implemented sequentially in a minimum of 100 villages serviced by an ICMV. The villages will be grouped into 11 blocks of 9 villages, with each block transitioned from control phase (before introduction of the personal protection package) to intervention phase (after introduction of the personal protection package) at monthly intervals in random order. This follows an initial one-month baseline period at the start of the study period where all villages will not be exposed to the personal protection package exclusively.

For this proposed stepped-wedge cluster randomized controlled study, it is estimated that approximately 30 RDTs per month will be tested in each study site (village/worksite) and there will be 36,000 MMP tests over 12 months in 100 villages/worksites. It will be undertaken yielding a relative minimum detectable difference of 40% in odds of RDT-detectable malaria infection (assuming a village intraclass correlation [ICC]= 0.42 [6]; 5% significance; 80% power and 1% RDT malaria prevalence).

For the stepped-wedged cluster randomized trial, both descriptive and primary outcome trial analyses will be performed. In both analyses, sampling weights will be derived and applied in analyses where village selection probabilities are not equal - possible if the achieved number of villages sampled across townships varies. Furthermore, cluster robust standard errors will be used in all descriptive analyses given the complex sampling design. Differences in prevalence of malaria infections will be estimated across intervention and control periods using generalized linear mixed modelling (e.g. logit link function and binomial distribution).

Being tested
Personal protection package
Keywords
malaria, prevention, vector, migrant, elimination, vivax, falciparum, community-delivered, intervention
Medical subject headings
Malaria

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Personal protection packageOther

    The personal protection package will be distributed to mobile and migrant peoples in each village according to the stepped wedge design.

Study groups in NCT05025761
Study groupRoleWhat they receive
Personal protection packageExperimentalA personal protection package that includes Long-lasting insecticidal hammock net (LLIHN),insect repellent (DEET), Insecticide-treated clothes (ITC), and mobile and migrant population-tailored behavioural change communication (BCC) package
Receives: Other: Personal protection package
ControlNo interventionNo personal protection package

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Plasmodium spp. infection diagnosed by RDT

    Change in the number of Plasmodium spp. infections detected by RDT per week per village (SD Bioline P.f/P.v)

    Measured: Assessed weekly, longitudinally over 12 months

Secondary outcomes (9)
  1. Symptomatic malaria diagnosed by RDT

    Change in the number of symptomatic Plasmodium spp. infections detected by RDT per week per village

    Measured: Assessed weekly, longitudinally over 12 months

  2. Plasmodium spp. infection as determined by polymerase chain reaction (PCR)

    Change in the number of Plasmodium spp. infections as determined by PCR using from RDT cassettes and dried blood spots

    Measured: Assessed weekly, longitudinally over 12 months

  3. Plasmodium spp. drug resistance mutations

    Prevalence and change in the number of Plasmodium spp. drug resistance mutations as determined by PCR from RDT cassettes and dried blood spots

    Measured: Assessed weekly, longitudinally over 12 months

  4. Prevalence of antibodies to Plasmodium spp.

    Prevalence of antibodies to Plasmodium spp. determined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples

    Measured: Assessed weekly, longitudinally over 12 months

  5. Levels of antibodies to Plasmodium spp.

    Levels of antibodies to Plasmodium spp. determined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples

    Measured: Assessed weekly, longitudinally over 12 months

  6. Prevalence of antibodies to vector salivary antigens

    Prevalence of antibody biomarkers of vector exposure determined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples

    Measured: Assessed weekly, longitudinally over 12 months

  7. Levels of antibodies to vector salivary antigens

    Levels of antibody biomarkers of vector exposure determined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples

    Measured: Assessed weekly, longitudinally over 12 months

  8. Levels of knowledge, attitude and practice regarding malaria prevention among MMPs (qualitative research)

    Focus group discussions

    Measured: At 12 months

  9. Proportion of survey respondents (MMPs) who accept and are willing to use/ did use the personal protection package according to the protocol

    Focus group discussions; Questionnaire

    Measured: At 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Aug 2021
  2. Study start1 Jan 2022 (estimated)
  3. Primary completionJun 2022 (estimated)
  4. Study completionJun 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Model description
Stepped-wedge cluster-randomized controlled trial (one-way crossover) with nested mixed methods study
Masking
None (open label)
Enrolment
1,200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05025761
Sponsor's protocol ID
260/21_forest_Myanmar
Status last verified
Aug 2021
First submitted
16 Aug 2021
Last updated
4 Nov 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Personal protection package in people with Plasmodium Falciparum Infection, run by Macfarlane Burnet Institute for Medical Research and Public Health Ltd.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Freya JI Fowkes, DPhil (+61385062310, freya.fowkes@burnet.edu.au), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Plasmodium spp. infection diagnosed by RDT (time frame: Assessed weekly, longitudinally over 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in